Procaine Benzylpenicillin

drug
On this page

Also known as BicillinCilicaine syringeDepocillinE707

Summary

Procaine Benzylpenicillin (CHEMBL1628385) is an approved small molecule (ATC J01CE09); indicated across 1 condition including bacterial infectious disease.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: J01CE09
  • Indications: 1 condition
  • Chemistry: 570.7 Da · C29H38N4O6S

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1628385
NameProcaine Benzylpenicillin
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID5903
ChEBICHEBI:52154
ATCJ01CE09
Molecular formulaC29H38N4O6S
Molecular weight570.7
InChIKeyWHRVRSCEWKLAHX-LQDWTQKMSA-N

SMILES: CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C

IUPAC name: 2-(diethylamino)ethyl 4-aminobenzoate;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

Also known as: Bicillin, Cilicaine syringe, Depocillin, E707, Procaine benzylpenicillin, PROCAINE BENZYLPENICILLIN

Parent form; salt/anhydrous children: CHEMBL1200936

Patent coverage: 1,606 distinct patent families (4,730 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,088 (65%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.